Patents by Inventor Peter Matthiessen

Peter Matthiessen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20250099559
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: November 19, 2024
    Publication date: March 27, 2025
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 12178861
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: December 23, 2022
    Date of Patent: December 31, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20230130866
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: December 23, 2022
    Publication date: April 27, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMAPANY LIMITED
    Inventors: Peter MATTHIESSEN, Peter L. TURECEK, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 11564979
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: January 31, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Recombinant VWF formulations
    Patent number: 11191837
    Abstract: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: December 7, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Peter Matthiessen, Peter Turecek, Hans-Peter Schwarz, Kurt Schnecker
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20200376098
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: July 21, 2020
    Publication date: December 3, 2020
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter MATTHIESSEN, Peter L. TURECEK, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 10758599
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 1, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20190247475
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: February 14, 2019
    Publication date: August 15, 2019
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 10238720
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 26, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20180207245
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 26, 2018
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 9937244
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 10, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20170112906
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 9572778
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: February 21, 2017
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20160375111
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: May 3, 2016
    Publication date: December 29, 2016
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Ethanol dependence of alpha1 antitrypsin C-terminal Lys truncation by basic carboxypeptidases
    Patent number: 9512172
    Abstract: Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: December 6, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Methods for modeling protein stability
    Patent number: 9388452
    Abstract: The present invention relates to a method for determining the highest temperature that is suitable for performing accelerated protein stability studies, as well as to a method for modeling real-time protein stability from accelerated stability data generated at said temperature.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: July 12, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventor: Peter Matthiessen
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 9351935
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 31, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • RECOMBINANT VWF FORMULATIONS
    Publication number: 20150216983
    Abstract: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 6, 2015
    Inventors: Peter Matthiessen, Peter Turecek, Hans-Peter Schwarz, Kurt Schnecker
  • Method for the validatable inactivation of pathogens in a biological fluid by irradiation
    Patent number: 8986607
    Abstract: A validatable method for determining a photochemically effective dose for inactivating pathogens in a fluid sample is described herein. In particular, the instant invention covers methods for determining a photochemically effective dose sufficient to inactivate pathogens in a biological sample while leaving biologically active substances of interest unaffected. A batch irradiation reactor effective for inactivating pathogens in biological samples is also described.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: March 24, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel R. Boggs
  • ETHANOL DEPENDENCE OF ALPHA1 ANTITRYPSIN C-TERMINAL LYS TRUNCATION BY BASIC CARBOXYPEPTIDASES
    Publication number: 20140309176
    Abstract: The present invention provides methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same.
    Type: Application
    Filed: May 27, 2014
    Publication date: October 16, 2014
    Inventors: Peter Matthiessen, Alfred Weber, Peter Turecek, Hans-Peter Schwarz